Prostate Cancer

The PSA test is a blood test used primarily to screen for prostate cancer.(Instagram) Prostate Cancer: 6 warning signs that men should not miss Many cases of prostate cancer go undetected till advanced stage as there are hardly any significant symptoms initially. By Parmita Uniyal UPDATED ON AUG 31, 2021 07:40 PM IST Prostate cancer, one of the most common cancers that affect men, mostly after the age of 60, is not easily detectable at initial stages. Symptoms are more prominent at advanced stage when it has spread to other parts of the body. This is the reason experts advise that men should pay attention to certain warning signs that may indicate trouble, and get screened for prostate cancer. Dr S K Pal, Urologist, Apollo Spectra Delhi, Nehru Enclave, explains more about the cancer and its warning signs. Some facts about prostate "The prostate is a small walnut sized gland situated in the pelvic region of a man next to the bladder. Yo

The Food and Drug Administration (FDA) has updated the indication for Keytruda (pembrolizumab) to include the treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for any platinum-containing chemotherapy. In addition, the agency converted this specific indication from an accelerated approval to a full (or regular) approval, according to a release. The anti-PD-1 therapy was previously indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin-based chemotherapy, those whose tumors expressed PD-L1 or in patients ineligible for any platinum-containing chemotherapy regardless of their PD-L1 status. Anti-PD-1 therapy utilizes the body's immune system to find and destroy cancer cells. The approval of this indication was based on the duration of response and tumor response rate. In addition, the FDA's Oncologic Drugs Advisory Committee met earlier this year, where membe

Introduction Waldenström's macroglobulinemia (WM) is a B-cell lymphoproliferative disorder which is defined by bone marrow (BM) infiltration by small lymphocytes, lymphoplasmacytoid cells and plasma cells together with the presence of a detectable monoclonal immunoglobulin M (IgM). 1,2 According to the 2008 World Health Organization (WHO) classification system of lymphoid neoplasms, the pathological disorder underlying WM is a lymphoplasmacytic lymphoma (LPL). 3 By the end of 2011, a remarkable fact that has changed the view of WM was presented at this year annual meeting of the American Society of Hematology, as it was the presence of the MYD88 L265P mutation in most cases of this disease, 4 which has been highlighted in the last 2016 WHO classification of lymphoid malignancies. 5 Other recent advances in the genomic profiling of patients with Waldenström macroglobulinemia (WM) have enhanced our understanding of its pathogenesis. 6,7 Thus, the highly recurring somatic muta

Although environmental and lifestyle factors often cause lung cancer, the disease can sometimes be genetic. Some genetic mutations that contribute to lung cancer run in families, but others do not. The World Health Organization (WHO) states that lung cancer was the second most common cancer worldwide in 2020. In this year, it caused 1.8 million deaths, making it the most common cause of death due to cancer. Both genetic and environmental factors can cause lung cancer. However, smoking remains the primary cause of lung cancer, being responsible for about 80–90% of cases. Some experts estimate that a genetic predisposition to lung cancer contributes to approximately 8% of cases. Some of these genetic risk factors are inherited, meaning that they run in families. However, other genetic changes are not inherited. A person's genes may mutate because of environmental factors, such as smoking and exposure to pollution. Read more to learn about the genetic causes of lung cancer, whether o

August 30, 2021 3 min read Source/Disclosures Published by: Source: Lopes RD, et al. Hot Line: PRONOUNCE. Presented at: European Society of Cardiology Congress; Aug. 27-30, 2021 (virtual meeting). Disclosures: PRONOUNCE was sponsored by Ferring Pharmaceuticals. Lopes reports research contracts with Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer and Sanofi and consultant fees, royalties and/or is owner/stockholder in Bayer, Boehringer Ingelheim, Daiichi Sankyo, Merck and Portola. Suter reports receiving grant support from Amgen. ADD TOPIC TO EMAIL ALERTS

Introduction The incidence of intraocular metastases is about 8%–10%. 1 Approximately 88% of eye metastases occur in the choroid, 2 with the majority originating from breast cancer (47%) and lung cancer (21%). 2,3 The clinical symptoms of lung cancer with choroid metastases (CM) are apparent, and approximately 35% of ocular metastases are detected prior to diagnosis of lung cancer. 2 Timely diagnosis and interventions for such patients are extremely important because of the poor prognosis. Ocular radiotherapy is considered a standard treatment option for intraocular metastatic tumors. Subsequently, other local or systemic treatments have gradually emerged in the setting of well-established cancer therapeutics, while various treatment modalities and sophisticated combination approaches remain controversial. Epidemiology Metastases are the most common ocular malignancies, with the uvea being the site most often affected. Approximately, 88% of metastases occur in the posterio